Personal prostate-specific antigen screening and treatment choices for localized prostate cancer among expert physicians

Christopher Wallis, Douglas Cheung, Laurence Klotz, Venu Chalasani, Ricardo Leao, Juan Garisto, Gerard Morton, Robert Nam, Juan Garisto, Ian Tannock, Raj Satkunasivam

Abstract


Introduction: We aimed to determine the personal practices of urologists, radiation oncologists, and medical oncologists regarding prostate cancer screening and treatment using the physician surrogate method, which seeks to identify acceptable healthcare interventions by ascertaining interventions physicians select for themselves.

Methods: A hierarchical, contingent survey was developed through a consensus involving urologists, medical oncologists, and radiation oncologists. It was piloted at the University of Toronto and then circulated to urologists, radiation oncologists, and medical oncologists through professional medical societies in the U.S., Canada, Central and South America, Australia, and New Zealand. The primary outcome was physicians’ personal choices regarding prostate-specific antigen (PSA) screening and the secondary outcome was treatment selection among those diagnosed with prostate cancer.

Results: A total of 869 respondents provided consent and completed the survey. Of these, there were 719 urologists, 89 radiation oncologists, nine medical oncologists, and 53 undisclosed specialists. Most (784 of 869 respondents; 90%) endorsed past or future screening for themselves (among male physicians) or for relatives (among female physicians). Among urologists and radiation oncologists making prostate cancer treatment decisions, there was a significant correlation between physician specialty and the treatment selected (Phi coefficient=0.61; p=0.001).

Conclusions: Physicians who routinely treat prostate cancer are likely to undertake prostate cancer screening themselves or recommend it for immediate family members. Treatment choice is influenced by the well-recognized specialty bias.


Full Text:

EPUB (DRAFT)

References


Moyer VA, Force USPST. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2012;157:120-34.

Canadian Task Force on Preventive Health C, Bell N, Connor Gorber S, Shane A, Joffres M, Singh H, et al. Recommendations on screening for prostate cancer with the prostate-specific antigen test. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2014;186:1225-34.

Carter HB, Albertsen PC, Barry MJ, Etzioni R, Freedland SJ, Greene KL, et al. Early detection of prostate cancer: AUA Guideline. The Journal of urology. 2013;190:419-26.

Cary KC, Punnen S, Odisho AY, Litwin MS, Saigal CS, Cooperberg MR, et al. Nationally representative trends and geographic variation in treatment of localized prostate cancer: the Urologic Diseases in America project. Prostate cancer and prostatic diseases. 2015;18:149-54.

Ubel PA, Angott AM, Zikmund-Fisher BJ. Physicians recommend different treatments for patients than they would choose for themselves. Arch Intern Med. 2011;171:630-4.

Mackillop WJ, Ward GK, O'Sullivan B. The use of expert surrogates to evaluate clinical trials in non-small cell lung cancer. British journal of cancer. 1986;54:661-7.

Moore MJ, O'Sullivan B, Tannock IF. How expert physicians would wish to be treated if they had genitourinary cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1988;6:1736-45.

Kim SP, Karnes RJ, Nguyen PL, Ziegenfuss JY, Thompson RH, Han LC, et al. A national survey of radiation oncologists and urologists on recommendations of prostate-specific antigen screening for prostate cancer. BJU international. 2014;113:E106-11.

Zettler M, Mollon B, da Silva V, Howe B, Speechley M, Vinden C. Family physicians' choices of and opinions on colorectal cancer screening modalities. Can Fam Physician. 2010;56:e338-44.

Scherr KA, Fagerlin A, Hofer T, Scherer LD, Holmes-Rovner M, Williamson LD, et al. Physician Recommendations Trump Patient Preferences in Prostate Cancer Treatment Decisions. Med Decis Making. 2016.

Kim SP, Gross CP, Nguyen PL, Smaldone MC, Thompson RH, Shah ND, et al. Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer. Prostate cancer and prostatic diseases. 2014;17:163-9.

Fowler FJ, Jr., McNaughton Collins M, Albertsen PC, Zietman A, Elliott DB, Barry MJ. Comparison of recommendations by urologists and radiation oncologists for treatment of clinically localized prostate cancer. JAMA : the journal of the American Medical Association. 2000;283:3217-22.




DOI: http://dx.doi.org/10.5489/cuaj.4736

Comments on this article

View all comments
 |  Add comment